Evaluation of Intermittent Ibrutinib Administration in Patients with Chronic Lymphocytic Leukemia

The primary objective of the study is to evaluate the efficacy of **intermittent ibrutinib** treatment in patients with **chronic lymphocytic leukemia**. This is clinically relevant as it aims to determine whether a non-continuous dosing regimen can maintain therapeutic benefits while potentially reducing side effects and improving patient quality of life. The study does not specify any secondary objectives.

The clinical trial involves participants diagnosed with **chronic lymphocytic leukemia**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and specific inclusion or exclusion criteria have not been disclosed. The trial aims to gather data from a diverse group of individuals to ensure comprehensive results.

The clinical trial is designed to evaluate the efficacy and safety of **intermittent ibrutinib** in patients with **chronic lymphocytic leukemia**. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated duration of the trial spans from December 1, 2017, to December 31, 2025. Participants will be randomly assigned to receive either the investigational treatment or a control, with neither the participants nor the investigators aware of the group assignments to ensure unbiased results.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful enrollment, participants will attend regular follow-up visits at specified intervals to monitor their response to the treatment and any adverse effects. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments are conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the study is determined by the trial's duration, which may vary depending on individual response and adherence to the protocol. Conditions that may lead to early termination from the study include significant adverse events, withdrawal of consent, or non-compliance with study procedures. The trial aims to provide valuable insights into the treatment of chronic lymphocytic leukemia, contributing to the advancement of therapeutic options for this condition.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is in Phase 3 and is expected to conclude by December 31, 2025. The recruitment for the trial began on December 1, 2017. The trial is categorized under trial category 1, with a trial category ID of 14590. The efficacy of the intervention will be assessed through parameters that are not specified in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not detailed in the available information. The trial's primary and secondary endpoints, as well as any specific tools or instruments used for efficacy assessments, are not mentioned in the source material.